These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 21075264)

  • 1. Progress in vaccines, progress in health economics.
    Annemans L
    Vaccine; 2010 Nov; 28 Suppl 6():G1-2. PubMed ID: 21075264
    [No Abstract]   [Full Text] [Related]  

  • 2. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model.
    De Wals P; Black S; Borrow R; Pearce D
    Clin Ther; 2009 Oct; 31(10):2152-69. PubMed ID: 19922887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New vaccines against otitis media: projected benefits and cost-effectiveness.
    O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA
    Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High cost is the primary barrier reported by physicians who prescribe vaccines not included in India's Universal Immunization Program.
    Kahn GD; Thacker D; Nimbalkar S; Santosham M
    J Trop Pediatr; 2014 Aug; 60(4):287-91. PubMed ID: 24567310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Advances in vaccines and invasive disease in children].
    Moraga Llop FA
    Rev Esp Quimioter; 2001 Dec; 14(4):319-30. PubMed ID: 11856977
    [No Abstract]   [Full Text] [Related]  

  • 6. Experience of vaccination against invasive bacterial diseases in Veneto region (north east Italy).
    Russo F; Pozza F; Napoletano G; Zanella F; Baldovin T; Lazzari R; Cocchio S; Baldo V
    J Prev Med Hyg; 2012 Jun; 53(2):113-5. PubMed ID: 23240172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age- and cause-specific childhood mortality in Lombok, Indonesia, as a factor for determining the appropriateness of introducing Haemophilus influenzae type b and pneumococcal vaccines.
    Nelson CM; Sutanto A; Gessner BD; Suradana IG; Steinhoff MC; Arjoso S
    J Health Popul Nutr; 2000 Dec; 18(3):131-8. PubMed ID: 11262765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The heptavalent conjugate pneumococcal vaccine and its implications for managed care--clinical overview and roundtable discussions.
    Alexander PG; Chartrand SA; Davies TJ; Gaines BM; Oster G; Shurin P; Tamsky L; Thornton DK; Wittert W
    Manag Care Interface; 2001; Suppl C():10-28; quiz 29-30. PubMed ID: 11724029
    [No Abstract]   [Full Text] [Related]  

  • 9. Vaccines: worth paying for the value returned.
    Grabenstein JD
    Ann Pharmacother; 2002 Sep; 36(9):1471-2. PubMed ID: 12229878
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-effectiveness of universal pneumococcal vaccination for infants in Italy.
    Lucioni C; Mazzi S
    Vaccine; 2006 Mar; 24(11):1735. PubMed ID: 16356601
    [No Abstract]   [Full Text] [Related]  

  • 11. Challenges in cost-effectiveness analyses of hospital interventions to improve quality.
    Davis MM
    Infect Control Hosp Epidemiol; 2008 May; 29(5):395-7. PubMed ID: 18419359
    [No Abstract]   [Full Text] [Related]  

  • 12. The remaining challenge of pneumonia: the leading killer of children.
    Dagan R; Bhutta ZA; de Quadros CA; Garau J; Klugman KP; Khuri-Bulos N; Levine O; Saha SK; Sow S; Were F; Yang Y
    Pediatr Infect Dis J; 2011 Jan; 30(1):1-2. PubMed ID: 21076365
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands.
    Postma MJ; Heijnen ML; Beutels P; Jager JC
    Expert Rev Vaccines; 2003 Aug; 2(4):477-82. PubMed ID: 14711333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pneumonia vaccine protocol could save money and lives.
    Levenson D
    Rep Med Guidel Outcomes Res; 2002 Mar; 13(5):5-7. PubMed ID: 12440407
    [No Abstract]   [Full Text] [Related]  

  • 15. [Splenectomy and pneumococcal vaccination].
    Postma MJ; Heijnen MA; de Vries R; Beutels P; Jager JC
    Ned Tijdschr Geneeskd; 2003 Jun; 147(23):1141-2; author reply 1142. PubMed ID: 12822527
    [No Abstract]   [Full Text] [Related]  

  • 16. Residual economic burden of Streptococcus pneumoniae- and nontypeable Haemophilus influenzae-associated disease following vaccination with PCV-7: a multicountry analysis.
    Talbird SE; Taylor TN; Caporale J; Ismaila AS; Gomez J
    Vaccine; 2010 Nov; 28 Suppl 6():G14-22. PubMed ID: 21075265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of early and late vaccination with Haemophilus influenzae type b conjugate and pneumococcal polysaccharide vaccines after allogeneic BMT.
    Parkkali T; Käyhty H; Ruutu T; Volin L; Eskola J; Ruutu P
    Bone Marrow Transplant; 1996 Nov; 18(5):961-7. PubMed ID: 8932852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pneumococcal vaccination; arguments for informing parents about the options available].
    Beaujean DJ; Verweij MF; van Steenbergen JE
    Ned Tijdschr Geneeskd; 2005 Apr; 149(17):909-11. PubMed ID: 15884402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination--a review (2002-2006).
    Beutels P; Thiry N; Van Damme P
    Vaccine; 2007 Feb; 25(8):1355-67. PubMed ID: 17208339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemophilus influenzae type b diseases in Asia.
    Lau YL
    Bull World Health Organ; 1999; 77(11):867-8. PubMed ID: 10612880
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.